Live Webcast:
Evaluation, Treatment, and Non-Stigmatizing Care for Adolescents with Obesity: Critical Components of Future Health
There are now nearly 15 million children in the United States suffering with obesity, reflecting a steep trajectory over the past few decades that firmly establish it both as a chronic disease and a critical health imperative. In 2023, the American Academy of Pediatrics (AAP) joined other organizations by releasing practice guidelines to emphasize obesity as a chronic disease, not a failure of character or willpower, that is linked to a complex pathophysiology involving energy balance dysregulation and organ system impairment. The new guidelines provide pathways that may include a combination of behavioral changes (eg, nutritious food, ample physical activity) with one of four FDA-approved drugs for childhood obesity, including semaglutide, liraglutide, orlistat, and phentermine/topiramate ER. Indications for bariatric surgery are also outlined.
This live, educational webcast titled, Evaluation, Treatment, and Patient Buy-In for Adolescents with Obesity, will feature expert faculty leading a conversation on how to achieve an equitable, universal approach to treating patients with obesity in the pediatric setting. The discussion will provide learners with a plan to evaluate patients, consider their social determinants of health, initiate appropriate therapies, and monitor treatment. Strategies to implement shared decision-making and other empathetic communications will encourage long-term patient engagement.
Register here:
CMEO Webcast
Live Webcast: Wednesday, June 28th, 2023
6:30 PM - 7:30 PM ET
This activity offers CE credit for:
-
Interprofessional (IPCE) 1.0
-
Physicians (ACCME) 1.0
-
Nurses (ANCC) 1.0
-
Pharmacists/Pharmacy Tech (ACPE) 1.0
-
PAs (AAPA) 1.0
-
Pediatricians (ABP MOC) 1.0
-
Royal College MOC
-
MIPS Improvement Activity
Credit Expiration Date: 06/28/2024
By entering your mobile phone number you agree that CME Outfitters can send you periodic text messages about CME/CE activities. This free service is FCC CAN-SPAM compliant. You may update message preferences or unsubscribe at any time. Check your wireless provider for any message and data rates that may apply.
Expert Faculty

Flagstaff, AZ

Massachusetts General Hospital
Associate Professor of Medicine and Pediatrics
Harvard Medical School
Boston, MA
Learning Objectives
At the end of this CME/CE activity, participants should be able to:
- Integrate equitable and universal AAP guidelines for evaluating adolescents for obesity-related comorbidities in clinical practice.
- Utilize simplified algorithms for initiating, monitoring, and continuing therapy long-term to initiate early treatment for obesity in adolescents in pediatric settings.
- Employ communication strategies with adolescents to gain patient buy-in to treat obesity long term.
Financial Support
Supported by an educational grant from Novo Nordisk, Inc.
Target Audience
Physicians, pharmacists, nurse practitioners (NPs), and physician associates (PAs) specializing in pediatrics.
Credit Information
Jointly Accredited Provider
Interprofessional (IPCE) 1.0
Physicians (ACCME) 1.0
Nurses (ANCC) 1.0
Pharmacists/Pharmacy Tech (ACPE) 1.0
Activity UAN: JA0007185-0000-23-064-L01-P
PAs (AAPA) 1.0
ABIM MOC
Royal College MOC
MIPS Improvement Activity
Disclosure Declaration
It is the policy of CME Outfitters, LLC, to ensure independence, balance, objectivity, and scientific rigor and integrity in all of their CE activities. Faculty must disclose to the participants any relationships with commercial companies whose products or devices may be mentioned in faculty presentations, or with the commercial supporter of this CE activity. CME Outfitters, LLC, has evaluated, identified, and mitigated any potential conflicts of interest through a rigorous content validation procedure, use of evidence-based data/research, and a multidisciplinary peer review process.
Dr. Armstrong reports no financial relationships to disclose.
Dr. Stanford reports the following financial relationships:
Consultant: Boehringer Ingelheim; Calibrate Health, Inc.; Currax Pharmaceuticals LLC.; Gelesis; LifeForce; Lilly; Novo Nordisk; Pfizer Inc.; Rhythm Pharmaceuticals, Inc.; Sweetch; Veri Inc.; and Vida Health
Dr. Golden reports the following financial relationships:
Advisory Board: Acella Pharmaceuticals, LLC; Currax Pharmaceuticals LLC; Gelesis; Lilly; Novo Nordisk; and WW International, Inc.
Consultant: SetPoint Medical
Speakers Bureau: Acella Pharmaceuticals, LLC; Currax Pharmaceuticals LLC; and Novo Nordisk
Other financial or material support: Royalties from Springer
Disclosures were obtained from the CME Outfitters, LLC staff; no disclosures to report:
- Joshua Caballero PharmD, BCPP, FCCP (peer reviewer)
- Evan Luberger (planning committee)
- Warren Beckman (planning committee)
- Susan H. Yarbrough, CHCP (planning committee)
- Sandra Caballero, PharmD (planning committee)
- Sharon Tordoff (planning committee)
Faculty of this CE activity may include discussions of products or devices that are not currently labeled for use by the FDA. The faculty have been informed of their responsibility to disclose to the audience if they will be discussing off-label or investigational uses (any uses not approved by the FDA) of products or devices
Obtaining Credit
Post-tests, credit request forms, and activity evaluations must be completed online (requires free account activation), and participants can print their certificate or statement of credit immediately (75% pass rate required). This website supports all browsers except Internet Explorer for Mac. For complete technical requirements and privacy policy, visit our Privacy & Confidentiality page.